Tenatumomab
Tenatumomab
Tenatumomab (pronunciation: te-na-tu-mo-mab) is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Pharmaceutical Research Associates.
Etymology
The name "Tenatumomab" is derived from the International Nonproprietary Names (INN), in which 'tena' refers to the target, 'tu' stands for the tumor, 'mo' indicates mouse origin, and 'mab' is indicative of monoclonal antibody.
Function
Tenatumomab is a type of immunotherapy that uses monoclonal antibodies to target specific cancer cells. These antibodies are designed to attach to antigens on the surface of cancer cells, allowing the immune system to better recognize and destroy them.
Related Terms
- Monoclonal Antibodies: A type of immune protein produced in the lab that can bind to substances in the body, including cancer cells. They are used in cancer treatment to enhance the body's immune response against cancer cells.
- Immunotherapy: A type of cancer treatment that helps your immune system fight cancer. It is a type of biological therapy.
- Antigen: A substance that the immune system recognizes and responds to, such as bacteria, viruses, and foreign substances in the blood.
- Pharmaceutical Research Associates: A global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services.
External links
- Medical encyclopedia article on Tenatumomab
- Wikipedia's article - Tenatumomab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski